不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
生物信息学鉴定 SPAG5 作为弥漫性大 B 细胞淋巴瘤的潜在预后生物标志物
英文原题：Bioinformatics Identification of SPAG5 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma.
查看英文原题
Bioinformatics Identification of SPAG5 as a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的生物信息学研究阐明了 SPAG5 在 DLBCL 中的表达谱、诊断潜力和预后意义，强调了 SPAG5 表达与肿瘤免疫景观之间复杂的相互作用。我们的发现表明 SPAG5 可能是 DLBCL 的候选预后标志物和潜在治疗靶点。
研究思路结论见上方概要
背景
弥漫性大B细胞淋巴瘤（DLBCL）是全球最常见的非霍奇金淋巴瘤类型。SPAG5是一种有丝分裂纺锤体蛋白，在DLBCL中发挥重要作用，其异常表达常与肿瘤生长、化疗耐药、局部复发及不良预后相关。
方法
使用Timer 2.0和Sanger Box 3.0对SPAG5在各种癌症类型中的表达进行了全面分析。随后，研究了SPAG5在DLBCL中的表达水平，并与正常样本进行了比较。然后生成受试者工作特征（ROC）曲线，以评估SPAG5对DLBCL的诊断性能。此外，还表征了SPAG5的功能作用，并分析了其对DLBCL患者免疫微环境的影响。还评估了其在预测免疫检查点状态和免疫治疗反应方面的潜力。
结果
SPAG5表达在多种癌症类型中表现出显著异质性，在DLBCL中明显上调。SPAG5的诊断效能为中等，AUC为0.75。SPAG5通过调控关键细胞过程对DLBCL进展产生多方面影响，包括细胞周期动态、染色体分离和DNA稳态。值得注意的是，SPAG5高表达患者的生存结局差于低表达患者。肿瘤免疫微环境分析揭示了一种独特模式：SPAG5高表达与静息NK细胞浸润增加相关，同时与Tregs和Tfh减少相关。
展开英文摘要原文
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most prevalent form of non-Hodgkin's lymphoma globally. SPAG5 , a mitotic spindle protein, plays a significant role in DLBCL, where its abnormal expression is often associated with tumor growth, chemotherapy resistance, local recurrence, and poor prognosis.
METHODS
A comprehensive analysis of SPAG5 expression across various cancer types was conducted using Timer 2.0 and Sanger Box 3.0. Subsequently, the expression levels of SPAG5 in DLBCL were investigated in comparison to normal samples. Receiver operating characteristic (ROC) curve was then generated to evaluate the diagnostic performance of SPAG5 for DLBCL. Furthermore, the functional role of SPAG5 was characterized, and its impact on the immune microenvironment of DLBCL patients was analyzed. Its potential in predicting immune checkpoint status and responses to immunotherapy was also evaluated.
RESULTS
SPAG5 expression demonstrated significant heterogeneity across various cancer types, with a marked upregulation in DLBCL. The diagnostic efficacy of SPAG5 was moderate, yielding an area under curve (AUC) of 0.75. SPAG5 exerted a multifaceted influence on DLBCL progression by regulating critical cellular processes, including cell cycle dynamics, chromosomal segregation, and DNA homeostasis. Notably, patients with elevated SPAG5 expression had poorer survival outcomes than those with low expression. Analysis of the tumor immune microenvironment revealed a distinct pattern: high SPAG5 expression correlated with increased infiltration of resting natural killer (NK) cells, while being associated with reduced presence of regulatory T cells (Tregs) and follicular helper T cells (Tfh).
CONCLUSION
Our bioinformatics study elucidated the expression profile, diagnostic potential, and prognostic significance of SPAG5 in DLBCL, emphasizing the complex interplay between SPAG5 expression and the tumor immune landscape. Our findings suggested SPAG5 could be a candidate prognostic marker and potential therapeutic target for DLBCL.
论文信息
- 作者
- Yan X、Liu L、Li J、Zhang H、Wang L、Liu L
- 单位
- Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.China
- 期刊
- Journal of blood medicine2025
- 原文标识
- PubMed 41244957 · DOI 10.2147/JBM.S546793
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →